Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire
Prospective assessment of the reliability, validity, and sensitivity to change of the functional assessment of cancer therapy-melanoma questionnaire
复制标题
DOI：
10.1002/cncr.23424
复制
发表时间：
2008-05-15
期刊：
影响因子：
6.2
通讯作者：
Palmer, J. Lynn
中科院分区：
文献类型：
--
作者：
Cormier, Janice N.;Ross, Merrick I.;Palmer, J. Lynn
背景。作者之前开发了用于癌症治疗功能评估 (FACT-Melanoma) 的黑色素瘤特异性模块，这是一种评估黑色素瘤患者生活质量 (QOL) 的工具。本研究检验了 FACT-Melanoma 的信度和效度。方法。黑色素瘤患者（N = 273；I-IV 期）在入组时完成了一系列调查问卷。该工具的有效性通过将 FACT-黑色素瘤评分与表现状态、疾病阶段、治疗状态和其他量表进行比较来检验，包括欧洲癌症研究和治疗组织生活质量问卷黑色素瘤模块、情绪状态概况和马洛-克罗恩社会期望量表。 1 周后对患者进行评估，以评估重测可靠性，并在 3 个月后对患者进行评估，以确定仪器对表现状态变化的敏感性。 结果。黑色素瘤子量表（Cronbach α =.85；r =.81）和总 FACT-Melanoma（α =.95；r =.90）的轮胎内部一致性和重测信度 (r) 非常出色。总体而言，正如预期的那样，这些量表与其他指标相关。对于晚期（III/IV 期）黑色素瘤、体能状态不佳和正在接受积极治疗的患者，FACT-黑色素瘤总评分以及身体健康、情绪健康、功能健康和黑色素瘤特异性量表评分较低。 FACT-黑色素瘤总分和身体健康得分对表现状态的变化敏感（分别为 P = .0012 和 P = .004）。结论。目前的研究结果表明，FACT-Melanoma 问卷对于黑色素瘤患者来说是一种可靠有效的工具，可用于评估临床试验中的生活质量。
BACKGROUND. The authors previously developed a melanoma-specific module for the Functional Assessment of Cancer Therapy (FACT-Melanoma), a tool for the assessment of quality of life (QOL) in patients with melanoma. The reliability and validity of the FACT-Melanoma was examined in this study.METHODS. Patients with melanoma (N = 273; stages I-IV) completed a battery of questionnaires at the time of enrollment. The validity of the instrument was examined by comparing FACT-Melanoma scores with performance status, disease stage, treatment status, and other scales, including the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Melanoma Module, the Profile of Mood States, and the Marlowe-Crowne Social Desirability Scale. Patients were assessed after 1 week to assess test-retest reliability and at 3 months to determine the sensitivity of the instrument to change in performance status.RESULTS. Tire internal consistency and test-retest reliability (r) of the melanoma subscale (Cronbach alpha =.85; r =.81) and the total FACT-Melanoma (alpha =.95; r =.90) were excellent. Overall, the scales were correlated with other measures, as anticipated. Total FACT-Melanoma scores, along with scores for physical wellbeing, emotional well-being, functional well-being, and melanoma-specific scales, were lower for patients with advanced (stage III/IV) melanoma, poor performance status, and patients who were receiving active treatment. The FACT-Melanoma total score and the score for physical well-being were sensitive to changes in performance status (P =.0012 and P =.004, respectively).CONCLUSIONS. The results Of the Current study indicated that the FACT-Melanoma questionnaire is a reliable and valid instrument for patients with melanoma that can be used for the assessment of QOL in clinical trials.